Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
暂无分享,去创建一个
[1] H. Gold,et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. , 1990, Circulation research.
[2] H. Gold,et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. , 1989, Circulation.
[3] D. Vaughan,et al. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. , 1989, The Journal of clinical investigation.
[4] G. FitzGerald,et al. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. , 1989, Circulation research.
[5] H. White,et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.
[6] F. Van de Werf,et al. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.
[7] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[8] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[9] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[10] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[11] H. Gold,et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.
[12] B. Sobel,et al. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.
[13] E. Topol,et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.
[14] K. M. Taylor,et al. EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.
[15] E. Braunwald,et al. Update from the Thrombolysis in Myocardial Infarction Trial. , 1987, Journal of the American College of Cardiology.
[16] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[17] O'Rourke St,et al. Inhibition of canine platelet aggregation by barbiturates. , 1986 .
[18] D. Collen,et al. Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.
[19] R. W. Brower,et al. RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.
[20] B E Sobel,et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.
[21] M. Ter-pogossian,et al. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. , 1983, Science.
[22] J. Sixma,et al. Morphology of the early hemostasis in human skin wounds: influence of acetylsalicylic acid. , 1978, Laboratory investigation; a journal of technical methods and pathology.
[23] J. Folts,et al. Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin , 1976, Circulation.
[24] D. Collen,et al. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. , 1976, Thrombosis research.
[25] T. Simon,et al. Thrombolytic therapy: Current status. , 1975, The New England journal of medicine.
[26] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[27] M. Scully,et al. Thrombolytic therapy. , 1968, British medical bulletin.
[28] Barr Jb,et al. HOME OR AWAY? , 1964, Lancet.
[29] M. Verstraete,et al. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.
[30] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .
[31] P. Trinder. Rapid determination of salicylate in biological fluids. , 1954, The Biochemical journal.
[32] B. Magnani,et al. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.
[33] Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.
[34] A. Jaffe,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.
[35] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[36] R. Albrecht,et al. Inhibition of canine platelet aggregation by barbiturates. , 1986, The Journal of laboratory and clinical medicine.
[37] T. Drake. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction , 1985 .
[38] H. Fritz,et al. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. , 1983, Arzneimittel-Forschung.
[39] J. White,et al. Arachidonate-induced platelet aggregation in the dog. , 1979, Thrombosis research.